- Home
- CLDX vs SRPT Comparison
CLDX vs SRPT Comparison
Compare CLDX & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLDX | SRPT |
|---|---|---|
| Founded | N/A | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.5B |
| IPO Year | 1995 | 2000 |
Fundamental Metrics
Financial Performance| Metric | CLDX | SRPT |
|---|---|---|
| Price | $33.29 | $20.77 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 29 |
| Target Price | ★ $46.60 | $25.85 |
| AVG Volume (30 Days) | 725.4K | ★ 2.4M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | $12,743,000.00 | ★ $2,198,237,000.00 |
| Revenue This Year | $111.39 | N/A |
| Revenue Next Year | $235.85 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 87.78 | 15.58 |
| 52 Week Low | $18.20 | $10.42 |
| 52 Week High | $35.83 | $44.14 |
Technical Indicators
Market Signals| Indicator | CLDX | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 53.45 | 46.98 |
| Support Level | $28.30 | $16.09 |
| Resistance Level | $35.18 | $23.31 |
| Average True Range (ATR) | 1.32 | 1.13 |
| MACD | -0.14 | -0.04 |
| Stochastic Oscillator | 40.19 | 40.90 |
Price Performance
Historical ComparisonAbout CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.